Novasep extends custom chiral separation capabilities
Novasep, a global leader in advanced separation technologies, has recently added a state-of-the-art cGMP pilot scale continuous chromatography unit in its Chasse sur Rhone, France facility.
Novasep, a global leader in advanced separation technologies, has recently added a state-of-the-art cGMP pilot scale continuous chromatography unit in its Chasse sur Rhone, France facility.
This ensures cost efficient separations of kilograms to tens of kilograms of pure enantiomer for clinical supplies.
Novasep operates six FDA-inspected facilities that manufacture APIs and advanced intermediates. Four of them integrate chiral separation services from preclinical to commercial supply. Novasep now operates ten pilot and commercial scale HPLC units, eight pilot and commercial scale Varicol systems (continuous chromatography systems) for producing batches up to 1 metric ton with a total capacity of more than 150 metric tons per annum.
This investment expands Novasep's chiral separation capabilities. The fully operational plant includes a Varicol8-80 unit, using 5 to 8 columns of 80mm i.d. and incorporates the latest PAT-compliant advanced control technology.
"Novasep, the world leader in preparative chromatography and the pioneer in continuous chromatography, was equipped with multiple HPLC and Varico systems," said Rene de Vaumas, vice-president of Exclusive Synthesis. "With this new investment, we are filling a gap in our service offerings. We are now extremely competitive for producing clinical batches of chiral compounds quality wise, time wise and cost wise."
De Vaumas added: "This addition follows our recent investments in three cGMP multi-step synthesis kilo-labs. Our customers will benefit from Novasep's continued commitment to improve and adapt its custom manufacturing capabilities to their evolving needs. "
